| Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study KN Chi, S Chowdhury, A Bjartell, BH Chung, ... Journal of Clinical Oncology 39 (20), 2294-2303, 2021 | 338 | 2021 |
| Apalutamide and overall survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... European urology 79 (1), 150-158, 2021 | 243 | 2021 |
| Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation … M May, S Brookman-Amissah, J Roigas, A Hartmann, S Störkel, ... European urology 57 (5), 850-858, 2010 | 216 | 2010 |
| Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort A Aziz, M May, M Burger, RJ Palisaar, QD Trinh, HM Fritsche, M Rink, ... European urology 66 (1), 156-163, 2014 | 209 | 2014 |
| Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node–negative urothelial carcinoma of … M May, E Herrmann, C Bolenz, S Brookman-May, A Tiemann, R Moritz, ... Annals of surgical oncology 18, 2018-2025, 2011 | 138 | 2011 |
| Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model … S Brookman-May, M May, SF Shariat, E Xylinas, C Stief, R Zigeuner, ... European urology 64 (3), 472-477, 2013 | 121 | 2013 |
| Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma M May, S Brookman-Amissah, S Pflanz, J Roigas, B Hoschke, F Kendel The British journal of radiology 82 (981), 724-731, 2009 | 104 | 2009 |
| Lymph node density affects cancer-specific survival in patients with lymph node–positive urothelial bladder cancer following radical cystectomy M May, E Herrmann, C Bolenz, A Tiemann, S Brookman-May, HM Fritsche, ... European urology 59 (5), 712-718, 2011 | 98 | 2011 |
| Time to recurrence is a significant predictor of cancer‐specific survival after recurrence in patients with recurrent renal cell carcinoma–results from a comprehensive multi … SD Brookman‐May, M May, SF Shariat, G Novara, R Zigeuner, L Cindolo, ... BJU international 112 (7), 909-916, 2013 | 97 | 2013 |
| Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 … W Otto, M May, HM Fritsche, D Dragun, A Aziz, M Gierth, L Trojan, ... Gender medicine 9 (6), 481-489, 2012 | 96 | 2012 |
| External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder P Nuhn, M May, M Sun, HM Fritsche, S Brookman-May, A Buchner, ... European urology 61 (1), 58-64, 2012 | 94 | 2012 |
| Latest evidence on the impact of smoking, sports, and sexual activity as modifiable lifestyle risk factors for prostate cancer incidence, recurrence, and progression: a … SD Brookman-May, R Campi, JDS Henriquez, T Klatte, JF Langenhuijsen, ... European urology focus 5 (5), 756-787, 2019 | 93 | 2019 |
| The phase 3 COU-AA-302 study of abiraterone acetate plus prednisone in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: stratified analysis based on … K Miller, J Carles, JE Gschwend, H Van Poppel, J Diels, ... European urology 74 (1), 17-23, 2018 | 81 | 2018 |
| Impact of resection technique on perioperative outcomes and surgical margins after partial nephrectomy for localized renal masses: a prospective multicenter study A Minervini, R Campi, BR Lane, O De Cobelli, F Sanguedolce, ... The Journal of Urology 203 (3), 496-504, 2020 | 78 | 2020 |
| Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised … F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, ... The Lancet Oncology 22 (11), 1541-1559, 2021 | 75 | 2021 |
| Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a M May, PJ Bastian, S Brookman-May, HM Fritsche, D Tilki, W Otto, ... Urologic Oncology: Seminars and Original Investigations 31 (7), 1141-1147, 2013 | 75 | 2013 |
| Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). EJ Small, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... Journal of Clinical Oncology 38 (15_suppl), 5516-5516, 2020 | 69 | 2020 |
| Post-void residual urine as a predictor of urinary tract infection—is there a cutoff value in asymptomatic men? M May, S Brookman-Amissah, B Hoschke, C Gilfrich, KP Braun, F Kendel The Journal of urology 181 (6), 2540-2544, 2009 | 68 | 2009 |
| Do we need new high-risk criteria for surgically treated renal cancer patients to improve the outcome of future clinical trials in the adjuvant setting? Results of a … I Wolff, M May, B Hoschke, R Zigeuner, L Cindolo, G Hutterer, L Schips, ... European Journal of Surgical Oncology (EJSO) 42 (5), 744-750, 2016 | 58 | 2016 |
| Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting M May, S Brookman-May, B Hoschke, C Gilfrich, F Kendel, S Baxmann, ... Cancer immunology, immunotherapy 59, 687-695, 2010 | 58 | 2010 |
